Brammer Bio
Viral Vector Development & Production / Gene Therapy Manufacturing – CDMO
Goals & Objectives
Brammer Bio was a gene therapy CDMO startup that astutely reacted and pivoted to an escalating and underserved industry demand for viral vector manufacturing. At launch, it needed a brand aligned to new modalities and a go-to-market strategy.
Strategic Approach
Brammer Bio’s launch timing took advantage of a re-energizing and rapid growth in the cell & gene therapy market. We built a scientific brand that also supported a growth strategy to stay ahead of the market with capacity. Brammer executed on this strategy by acquiring a Biogen facility and pivoting to viral vectors.
Meeting & Exceeding KPIs
A combination of modality expertise from its founding merger with Florida Biologix, which we highlighted through thought leadership content, and answering an intense industry need for viral vectors saw Brammer move from startup to market leader in under four years. Abundant outside interest culminated in acquisition by Thermo Fisher Scientific.
